3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
6
Phase 1
2
Phase 4
1
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Weight Loss
1
Sleep Initiation and Maintenance Disorders
1
Protein Deficiency
1
Prostatic Neoplasms
1
Prolactinoma
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Malnutrition
1
Kidney Neoplasms
1
Iron Deficiencies
1
Hemostasis
1
Delirium
1
Carcinoma, Renal Cell
1
Anemia
1
Interventions
Dexamethasone
11
Lenalidomide
10
Bortezomib
9
Zoledronic Acid
8
ixazomib
4
daratumumab
4
Melphalan
4
tocilizumab
3
Thalidomide
3
Cyclophosphamide
3
pomalidomide
2
carfilzomib
2
Prednisone
2
Kyphoplasty
2
Filgrastim
2
Doxorubicin
2
Calcium Dobesilate
2
zanubrutinib
1
talquetamab
1
pegylated granulocyte colony-stimulating factor
1
montelukast
1
isatuximab
1
ibrutinib
1
exifone
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
apixaban
1
Vaccination
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Multiple Myeloma
×
Standard of Care
×
Clear all
NCT07094048
2026-01-07
CHUQUL_HO001
CHU de Quebec-Universite Laval
Phase 4
Recruiting
80 enrolled